tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VALN Stock Latest News

Valneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile
Company AnnouncementsValneva’s IXCHIQ Chikungunya Vaccine Faces New UK Use Restrictions but Retains Positive Benefit–Risk Profile
3d ago
6K
VALN
Valneva and Instituto Butantan Launch Pilot Chikungunya Vaccination Campaign in Brazil
PremiumCompany Announcements
Valneva and Instituto Butantan Launch Pilot Chikungunya Vaccination Campaign in Brazil
13d ago
6K
VALN
Valneva Withdraws U.S. IXCHIQ Chikungunya Filings After FDA Clinical Hold
PremiumCompany Announcements
Valneva Withdraws U.S. IXCHIQ Chikungunya Filings After FDA Clinical Hold
27d ago
6K
VALN
Valneva withdraws BLA, IND application for Ixchiq in U.S.
PremiumThe Fly
Valneva withdraws BLA, IND application for Ixchiq in U.S.
28d ago
VALN
Valneva to Engage Investors at J.P. Morgan Conference Ahead of Key Lyme Vaccine Data
PremiumCompany Announcements
Valneva to Engage Investors at J.P. Morgan Conference Ahead of Key Lyme Vaccine Data
1M ago
6K
VALN
Valneva Regains Full Rights to Chikungunya Vaccine as Serum Institute License Ends
PremiumCompany AnnouncementsValneva Regains Full Rights to Chikungunya Vaccine as Serum Institute License Ends
2M ago
6K
VALN
Valneva, Serum Institute of India discontinue chikungunya vaccine pact
Premium
The Fly
Valneva, Serum Institute of India discontinue chikungunya vaccine pact
2M ago
VALN
Valneva Reports Positive Phase 2 Results for Chikungunya Vaccine in Children
Premium
Company Announcements
Valneva Reports Positive Phase 2 Results for Chikungunya Vaccine in Children
2M ago
6K
VALN
Valneva reports ‘positive’ final Phase 2 results for chikungunya vaccine
PremiumThe Fly
Valneva reports ‘positive’ final Phase 2 results for chikungunya vaccine
2M ago
VALN
Valneva Announces Strategic Consolidation of French Operations
PremiumCompany Announcements
Valneva Announces Strategic Consolidation of French Operations
3M ago
6K
VALN
Valneva Reports Nine-Month 2025 Financial Results and Updates on Vaccine Developments
PremiumCompany Announcements
Valneva Reports Nine-Month 2025 Financial Results and Updates on Vaccine Developments
3M ago
6K
VALN
Valneva SE Reports 2025 Nine-Month Financial Results
PremiumCompany Announcements
Valneva SE Reports 2025 Nine-Month Financial Results
3M ago
VALN
Valneva Se’s Earnings Call: Mixed Results and Future Prospects
PremiumCompany AnnouncementsValneva Se’s Earnings Call: Mixed Results and Future Prospects
3M ago
VALN
Valneva Reports Increased Revenues and Strategic Advances in Vaccine Development
Premium
Company Announcements
Valneva Reports Increased Revenues and Strategic Advances in Vaccine Development
3M ago
6K
VALN
Valneva’s Promising Future: Buy Rating Backed by Strong Prospects for Lyme Disease Vaccine and Robust Financial Health
Premium
Ratings
Valneva’s Promising Future: Buy Rating Backed by Strong Prospects for Lyme Disease Vaccine and Robust Financial Health
3M ago
VALN
Is VALN a Buy, Before Earnings?
PremiumPre-Earnings
Is VALN a Buy, Before Earnings?
3M ago
VALN
Valneva Reports Positive Phase 1 Results for Zika Vaccine Candidate
PremiumCompany Announcements
Valneva Reports Positive Phase 1 Results for Zika Vaccine Candidate
3M ago
6K
VALN
Valneva Secures $500 Million Financing to Bolster Vaccine Pipeline
PremiumCompany Announcements
Valneva Secures $500 Million Financing to Bolster Vaccine Pipeline
4M ago
6K
VALN
Valneva Reports Long-lasting Antibody Persistence for Chikungunya Vaccine
PremiumCompany Announcements
Valneva Reports Long-lasting Antibody Persistence for Chikungunya Vaccine
4M ago
6K
VALN
Valneva price target lowered to $13 from $14 at Guggenheim
PremiumThe FlyValneva price target lowered to $13 from $14 at Guggenheim
5M ago
VALN
Valneva Reports Positive Phase 2 Results for Lyme Disease Vaccine
Premium
Company Announcements
Valneva Reports Positive Phase 2 Results for Lyme Disease Vaccine
6M ago
6K
VALN
Valneva’s Stock: A Buy Rating Amid Overreaction and Promising Vaccine Prospects
Premium
Ratings
Valneva’s Stock: A Buy Rating Amid Overreaction and Promising Vaccine Prospects
6M ago
VALN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >